Baillie Gifford & Co. Lowers Stake in Illumina, Inc. $ILMN

Baillie Gifford & Co. decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 3.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,686,692 shares of the life sciences company’s stock after selling 54,461 shares during the period. Baillie Gifford & Co. owned 1.10% of Illumina worth $160,185,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Envestnet Portfolio Solutions Inc. raised its stake in shares of Illumina by 0.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock worth $1,152,000 after purchasing an additional 99 shares during the last quarter. Versant Capital Management Inc raised its position in Illumina by 8.9% during the third quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock worth $130,000 after acquiring an additional 111 shares during the period. Parkside Financial Bank & Trust lifted its stake in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after buying an additional 115 shares in the last quarter. Bouvel Investment Partners LLC boosted its holdings in Illumina by 2.3% in the 3rd quarter. Bouvel Investment Partners LLC now owns 6,129 shares of the life sciences company’s stock worth $582,000 after buying an additional 136 shares during the last quarter. Finally, Arkadios Wealth Advisors increased its stake in Illumina by 1.7% during the 2nd quarter. Arkadios Wealth Advisors now owns 9,130 shares of the life sciences company’s stock worth $871,000 after buying an additional 157 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $150.28 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The company has a market cap of $22.96 billion, a price-to-earnings ratio of 33.70, a price-to-earnings-growth ratio of 2.56 and a beta of 1.41. The stock’s 50-day moving average is $135.20 and its two-hundred day moving average is $113.14. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $155.53.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the company earned $1.14 EPS. The business’s quarterly revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Transactions at Illumina

In related news, Director Scott Gottlieb bought 500 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were bought at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the transaction, the director owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This trade represents a 1.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of research analyst reports. Barclays lifted their price target on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. UBS Group lifted their target price on shares of Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Canaccord Genuity Group increased their target price on shares of Illumina from $112.00 to $130.00 and gave the company a “hold” rating in a research report on Monday, December 22nd. Guggenheim raised their price target on shares of Illumina from $114.00 to $144.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $124.47.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.